Published January 24, 2024 | Version v1
Journal article Open

Activity of an oleanane-type tritrepenoid saponin from A. glycyphyllos on human recombinant MAO enzymes

Authors/Creators

  • 1. Medical University of Sofia, Sofia, Bulgaria

Description

For centuries, plants have been a leading point in the identification of potential therapeutic agents. Monoamine oxidase inhibition is a key mechanism in the treatment of various neurological and psychiatric diseases. Some triterpenoid saponins are reported to inhibit this enzyme. An extract from the aerial parts of Astragalus glycyphyllos was purified and separated by chromatographic techniques, which led to the isolation of one triterpene saponin. Its structure was analysed by ultra-high-performance liquid chromatography coupled with high-resolution electrospray ionisation mass spectrometry. The compound was subjected to a pharmacological study where human recombinant monoamine oxidase enzymes type A and B (hMAOA and hMAOB) were used. On the activity of hMAOA, the saponin had no effect, but on hMAOB, it exhibited statistically significant inhibition in comparison to the control, Selegiline. The compound could have potential in other models, so further investigations are required.

Files

PHAR_article_114786.pdf

Files (750.3 kB)

Name Size Download all
md5:7c5ee7e93cf3eccf482e22a203879c9c
681.3 kB Preview Download
md5:38b16e5a75b72981ddd13e2e60adba5a
69.0 kB Preview Download

Additional details

Cites
Publication: 10.1016/j.lfs.2019.03.057 (DOI)
Publication: 10.2174/1871527316666170124165222 (DOI)
Publication: 10.2174/1389450110607011513 (DOI)
Publication: 10.1016/j.pnpbp.2016.02.012 (DOI)
Publication: 10.1016/j.jep.2020.113519 (DOI)
Publication: 10.4137/PMC.S11375 (DOI)
Publication: 10.1016/B978-0-12-805120-7.00003-8 (DOI)
Publication: 10.3389/fnagi.2018.00437 (DOI)
Publication: 10.1006/abbi.1996.0510 (DOI)
Publication: 10.1016/S1535-5535(04)00251-5 (DOI)
Publication: 10.1002/jms.398 (DOI)
Publication: 10.3897/pharmacia.67.e50806 (DOI)
Publication: 10.1007/s11101-016-9462-4 (DOI)
Publication: 10.1007/s11101-014-9347-3 (DOI)
Publication: 10.1016/j.nurt.2008.10.035 (DOI)
Publication: 10.1590/s2175-97902019000318255 (DOI)
Publication: 10.1080/13102818.2019.1673209 (DOI)
Publication: 10.1016/0006-2944(76)90049-1 (DOI)
Publication: 10.1371/journal.pone.0001616 (DOI)
Publication: 10.1371/annotation/3c37bef4-bb5e-4f1e-8551-01afc006df90 (DOI)
Publication: 10.3390/molecules28124814 (DOI)
Publication: 10.1016/0014-4886(92)90055-U (DOI)
Publication: 10.1586/ern.13.60 (DOI)
Publication: 10.1093/brain/111.6.1441 (DOI)
Publication: 10.1186/s13195-017-0279-1 (DOI)
Publication: 10.1080/13102818.2023.2221752 (DOI)
Publication: 10.1080/14786419.2018.1491040 (DOI)
Publication: 10.1016/j.bjp.2018.10.002 (DOI)
Publication: 10.3897/pharmacia.70.e107989 (DOI)
Publication: 10.3390/metabo13070857 (DOI)
Publication: 10.1016/S0031-9422(00)00091-1 (DOI)
Publication: 10.1002/ptr.5246 (DOI)
Publication: 10.2174/0929867043364810 (DOI)
Publication: 10.1007/978-3-7091-8901-6_4 (DOI)
Publication: 10.1126/science.3875898 (DOI)
Publication: 10.1016/0304-3940(88)90794-X (DOI)
Publication: 10.1038/sj.bjp.0706464 (DOI)
Publication: 10.1038/nrn1883 (DOI)
Publication: 10.1016/j.foodchem.2010.05.050 (DOI)
Has part
Figure: 10.3897/pharmacia.71.e114786.figure1 (DOI)
Figure: 10.3897/pharmacia.71.e114786.figure3 (DOI)
Figure: 10.3897/pharmacia.71.e114786.figure4 (DOI)
Figure: 10.3897/pharmacia.71.e114786.figure2 (DOI)

References

  • Chand R, Anjum R, ul Ain Shakeel N (2019) Parkinson's disease: mechanisms, translational models and management strategies. Life Sciences 226: 77–90. https://doi.org/10.1016/j.lfs.2019.03.057
  • Dezsi L, Vecsei L (2017) Monoamine oxidase B inhibitors in Parkinson's disease. CNS & Neurological Disorders – Drug Targets 16(4): 425–439. https://doi.org/10.2174/1871527316666170124165222
  • Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, El ReFaey H, Carlson C (2006) Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Current Drug Targets 7(11): 1513–1529. https://doi.org/10.2174/1389450110607011513
  • Fišar Z (2016) Drugs related to monoamine oxidase activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 69: 112–124. https://doi.org/10.1016/j.pnpbp.2016.02.012
  • Georgieva A, Popov G, Shkondrov A, Toshkova R, Krasteva I, Kondeva-Burdina M, Manov M (2021) Antiproliferative and antitumour activity of saponins from Astragalus glycyphyllos on myeloid Graffi tumour. Journal of Ethnopharmacology 267: e113519. https://doi.org/10.1016/j.jep.2020.113519
  • Goldberg J, Bell C, Pollard D (2014) Revisiting the monoamine hypothesis of depression: a new perspective. Perspectives in Medicinal Chemistry 2014: 6. https://doi.org/10.4137/PMC.S11375
  • Gordon R, Woodruff T (2017) Chapter 3 – Neuroinflammation as a therapeutic target in neurodegenerative diseases. In: Baekelandt V, Lobbestael E (Eds) Disease-Modifying Targets in Neurodegenerative Disorders. Academic Press, 49–80. https://doi.org/10.1016/B978-0-12-805120-7.00003-8
  • Guarino A, Favieri F, Boncompagni I, Agostini F, Cantone M, Casagrande M (2018) Executive functions in Alzheimer disease: A systematic review. Frontiers in Aging Neuroscience 10: e437. https://doi.org/10.3389/fnagi.2018.00437
  • Hauptmann N, Grimsby J, Shih J, Cadenas E (1996) The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Archives of Biochemistry and Biophysics 335(2): 295–304. https://doi.org/10.1006/abbi.1996.0510
  • Held P, Buehrer L (2003) The SynergyTM HT: a unique multi-detection microplate reader for HTS and drug discovery. SLAS Technology 8(2): 44–49. https://doi.org/10.1016/S1535-5535(04)00251-5
  • Hvattum E, Ekeberg D (2003) Study of the collision-induced radical cleavage of flavonoid glycosides using negative electrospray ionization tandem quadrupole mass spectrometry. Journal of Mass Spectrometry 38(1): 43–49. https://doi.org/10.1002/jms.398
  • Ilieva V, Kondeva-Burdina M, Georgieva T (2020) In vitro analysis of the activity of human monoamine oxidase type B (hMAOB), treated with the cyanotoxin anatoxin-a: supposed factor of neurodegenerative diseases. Pharmacia 67(2): 111–114. https://doi.org/10.3897/pharmacia.67.e50806
  • Ilina K, Shkondrov A, Ionkova I, Zdraveva P (2016) Advances in phytochemistry, pharmacology and biotechnology of bulgarian Astragalus species. Phytochemistry Reviews 15(4): 567–590. https://doi.org/10.1007/s11101-016-9462-4
  • Ionkova I, Shkondrov A, Krasteva I, Ionkov T (2014) Recent progress in phytochemistry, pharmacology and biotechnology of Astragalus saponins. Phytochemistry Reviews 13(2): 343–374. https://doi.org/10.1007/s11101-014-9347-3
  • Jacobus P, Castagnoli N, Schwarzschild M, Chen J, Van der Schyf C (2009) Dual-target-directed drugs that block monoamine oxidase B and adenosine a2a receptors for Parkinson's disease. Neurotherapeutics 6(1): 141–151. https://doi.org/10.1016/j.nurt.2008.10.035
  • Kasabova-Angelova A, Kondeva-Burdina M, Mitkov J, Georgieva M, Tzankova V, Zlatkov A (2020) Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides. Brazilian Journal of Pharmaceutical Sciences 56: e18255. https://doi.org/10.1590/s2175-97902019000318255
  • Kondeva-Burdina M, Doytchinova I, Krasteva I, Ionkova I, Manov V (2019) Hepato-, neuroprotective effects and QSAR studies on flavoalkaloids and flavonoids from Astragalus monspessulanus. Biotechnology and Biotechnological Equipment 33(1): 1434–1443. https://doi.org/10.1080/13102818.2019.1673209
  • Kunio Y (1976) A simple fluorometric assay for lipoperoxide in blood plasma. Biochemical Medicine 15(2): 212–216. https://doi.org/10.1016/0006-2944(76)90049-1
  • Mallajosyula JK, Kaur D, Chinta S, Rajagopalan S, Rane A, Nicholls D, Di Monte D, Macarthur H, Andersen J (2008) MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLOS ONE 3(2): e1616. https://doi.org/10.1371/journal.pone.0001616
  • Mallajosyula JK, Kaur D, Chinta S, Rajagopalan S, Rane A, Nicholls D, Di Monte D, Macarthur H, Andersen J (2012) Correction: MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLOS ONE 7(8): 10. https://doi.org/10.1371/annotation/3c37bef4-bb5e-4f1e-8551-01afc006df90
  • Mateev E, Georgieva M, Mateeva A, Zlatkov A, Ahmad S, Raza K, Azevedo V, Barh D (2023) Structure-based design of novel MAO-B inhibitors: a review. Molecules (Basel, Switzerland) 28(12): 4814. https://doi.org/10.3390/molecules28124814
  • Naji JR, Harik S (1992) Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys. Experimental Neurology 115(2): 212–217. https://doi.org/10.1016/0014-4886(92)90055-U
  • Naoi M, Maruyama W, Inaba-Hasegawa K (2013) Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Review of Neurotherapeutics 13(6): 671–684. https://doi.org/10.1586/ern.13.60
  • Rajesh K, Mitchell M, Harik S (1988) Monoamine oxidases of the human brain and liver. Brain 111(6): 1441–1451. https://doi.org/10.1093/brain/111.6.1441
  • Schedin-Weiss S, Inoue M, Hromadkova L, Teranishi Y, Yamamoto N, Wiehager, Bogdanovic N, Winblad B, Sandebring-Matton A, Frykman S, Tjernberg L (2017) Monoamine oxidase B is elevated in alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels. Alzheimer's Research & Therapy 9(1): 1–57. https://doi.org/10.1186/s13195-017-0279-1
  • Shkondrov A, Hinkov A, Cvetkov V, Shishkova K, Todorov D, Shishkov S, Stambolov I, Yoncheva K, Krasteva I (2023) Astragalus Glycyphyllos L.: Antiviral activity and tablet dosage formulation of a standardized dry extract. Biotechnology & Biotechnological Equipment 37(1): e2221752. https://doi.org/10.1080/13102818.2023.2221752
  • Shkondrov A, Krasteva I, Bucar F, Kunert O, Kondeva-Burdina M, Ionkova I (2020) A new tetracyclic saponin from Astragalus glycyphyllos L. and its neuroprotective and hMAO-B inhibiting activity. Natural Product Research 34(4): 511–517. https://doi.org/10.1080/14786419.2018.1491040
  • Simeonova R, Vitcheva V, Kondeva-Burdina M, Popov G, Shkondrov A, Manov V, Krasteva I (2019) Alcesefoliside protects against oxidative brain injury in rats. Revista Brasileira de Farmacognosia 29(2): 221–227. https://doi.org/10.1016/j.bjp.2018.10.002
  • Stambolov I, Shkondrov A, Krasteva I (2023a) Astragalus glycyphyllos L.: Phytochemical constituents, pharmacology, and biotechnology. Pharmacia 70(3): 635–641. https://doi.org/10.3897/pharmacia.70.e107989
  • Stambolov I, Shkondrov A, Kunert O, Bucar F, Kondeva-Burdina M, Krasteva I (2023b) Cycloartane saponins from Astragalus Glycyphyllos and their in vitro neuroprotective, antioxidant, and hMAO-B-inhibiting effects. Metabolites 13(7): e857. https://doi.org/10.3390/metabo13070857
  • Stobiecki M (2000) Application of mass spectrometry for identification and structural studies of flavonoid glycosides. Phytochemistry 54(3): 237–256. https://doi.org/10.1016/S0031-9422(00)00091-1
  • Sun A, Xu X, Lin J, Xiuling Cui, Xu R (2015) Neuroprotection by saponins. Phytotherapy Research 29(2): 187–200. https://doi.org/10.1002/ptr.5246
  • Tipton K, Sinead B, O'Sullivan J, Davey G, Healy J (2004) Monoamine oxidases: certainties and uncertainties. Current Medicinal Chemistry 11(15): 1965–1982. https://doi.org/10.2174/0929867043364810
  • Waldmeier PC (1987) Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). In: Oreland L, Callingham B (Eds) Monoamine Oxidase Enzymes: Review and Overview. Springer Vienna, Vienna, 55–72. https://doi.org/10.1007/978-3-7091-8901-6_4
  • Westlund K, Denney R, Kochersperger L, Rose R, Abell C (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230(4722): 181–183. https://doi.org/10.1126/science.3875898
  • Willoughby J, Vivette G, Sandler M, Albanese A, Jenner P, Marsden CD (1988) Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP yoxicity. Neuroscience Letters 90(1): 100–106. https://doi.org/10.1016/0304-3940(88)90794-X
  • Youdim M, Bakhle Y (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. British Journal of Pharmacology 147(S1): S287–S296. https://doi.org/10.1038/sj.bjp.0706464
  • Youdim M, Edmondson D, Tipton K (2006) The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews Neuroscience 7(4): 295–309. https://doi.org/10.1038/nrn1883
  • Zhang W, Popovich D (2010) Behaviour of soyasapogenol b under optimised hydrolysis and esi mass spec conditions. Food Chemistry 123(4): 993–999. https://doi.org/10.1016/j.foodchem.2010.05.050